CN105120854B - 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 - Google Patents

新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 Download PDF

Info

Publication number
CN105120854B
CN105120854B CN201380038486.1A CN201380038486A CN105120854B CN 105120854 B CN105120854 B CN 105120854B CN 201380038486 A CN201380038486 A CN 201380038486A CN 105120854 B CN105120854 B CN 105120854B
Authority
CN
China
Prior art keywords
compound
alkyl
stat3
group
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380038486.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105120854A (zh
Inventor
梅利莎·L·菲谢尔
帕特里克·托马斯·贡宁
西纳·哈夫特舍纳里
布伦特·戴维·乔治·帕盖
塞谬尔·韦斯
赫马·阿蒂·卢奇曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uti Partners Ltd
University of Toronto
Indiana University Research and Technology Corp
Original Assignee
Uti Partners Ltd
University of Toronto
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Partners Ltd, University of Toronto, Indiana University Research and Technology Corp filed Critical Uti Partners Ltd
Priority to CN201910222566.1A priority Critical patent/CN110003104A/zh
Publication of CN105120854A publication Critical patent/CN105120854A/zh
Application granted granted Critical
Publication of CN105120854B publication Critical patent/CN105120854B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
CN201380038486.1A 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法 Expired - Fee Related CN105120854B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910222566.1A CN110003104A (zh) 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
US61/651,757 2012-05-25
PCT/US2013/042689 WO2013177534A2 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910222566.1A Division CN110003104A (zh) 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Publications (2)

Publication Number Publication Date
CN105120854A CN105120854A (zh) 2015-12-02
CN105120854B true CN105120854B (zh) 2019-04-09

Family

ID=49624538

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380038486.1A Expired - Fee Related CN105120854B (zh) 2012-05-25 2013-05-24 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
CN201910222566.1A Pending CN110003104A (zh) 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910222566.1A Pending CN110003104A (zh) 2012-05-25 2013-05-24 水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法

Country Status (9)

Country Link
US (3) US9650399B2 (https=)
EP (1) EP2854819B1 (https=)
JP (2) JP6290871B2 (https=)
CN (2) CN105120854B (https=)
BR (1) BR112014029439A2 (https=)
CA (1) CA2874057A1 (https=)
HK (1) HK1218709A1 (https=)
RU (1) RU2641903C2 (https=)
WO (1) WO2013177534A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2975936A4 (en) * 2013-03-22 2017-03-15 University of Hawaii Novel stat3 inhibitors
WO2015179956A1 (en) * 2014-05-30 2015-12-03 The Governing Council Of The University Of Toronto Sulfonamide compounds and their use as stat5 inhibitors
EP3570836A4 (en) * 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE STAT3 INHIBITORS
WO2020124262A1 (en) * 2018-12-21 2020-06-25 The Governing Council Of The University Of Toronto New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
CN115551490A (zh) * 2020-03-05 2022-12-30 詹皮克斯有限公司 α取代的STAT抑制剂及其组合物
AU2021232072A1 (en) * 2020-03-05 2022-10-20 Centessa Pharmaceuticals (Uk) Limited STAT inhibitory compounds and compositions
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途
CN118994047B (zh) * 2024-08-13 2026-02-10 中国药科大学 一种水杨醛衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1701941E (pt) * 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
BRPI0709916B8 (pt) * 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US7960434B2 (en) 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
CN102099352B (zh) * 2008-07-10 2014-02-26 一般社团法人创药分子Ip 以喹啉甲酰胺衍生物为有效成分的stat3抑制剂
US8586749B2 (en) 2009-04-06 2013-11-19 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
EP2975936A4 (en) * 2013-03-22 2017-03-15 University of Hawaii Novel stat3 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018868A1 (en) * 2010-08-02 2012-02-09 University Of Central Florida Research Foundation, Inc. Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain;Brent D. G. Page et al;《Bioorganic & Medicinal Chemistry Letters》;20110630;第21卷;第5605-5609页 *

Also Published As

Publication number Publication date
JP2015522551A (ja) 2015-08-06
CN105120854A (zh) 2015-12-02
JP6543366B2 (ja) 2019-07-10
US20190382422A1 (en) 2019-12-19
EP2854819A2 (en) 2015-04-08
JP6290871B2 (ja) 2018-03-07
US9650399B2 (en) 2017-05-16
RU2641903C2 (ru) 2018-01-23
US20150158894A1 (en) 2015-06-11
WO2013177534A2 (en) 2013-11-28
US20170267704A1 (en) 2017-09-21
HK1218709A1 (zh) 2017-03-10
RU2014152697A (ru) 2016-07-20
CA2874057A1 (en) 2013-11-28
JP2018109017A (ja) 2018-07-12
BR112014029439A2 (pt) 2017-06-27
EP2854819B1 (en) 2020-01-15
US10377780B2 (en) 2019-08-13
EP2854819A4 (en) 2016-06-15
CN110003104A (zh) 2019-07-12
WO2013177534A3 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CN105120854B (zh) 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
JP6887996B2 (ja) Ｔｅａｄ転写因子自己パルミトイル化阻害剤
ES2962679T3 (es) Forma cristalina del inhibidor de c-MET y su forma salina y método de preparación de las mismas
KR101298168B1 (ko) 스네일―ｐ５３ 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제
US10954258B2 (en) STAT3 dimerization inhibitors
CA2811265C (en) Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction
RU2584986C2 (ru) Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов
Xu et al. Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity
Miklossy et al. Hirsutinolide series inhibit Stat3 activity, alter GCN1, MAP1B, Hsp105, G6PD, vimentin, TrxR1, and importin α-2 expression, and induce antitumor effects against human glioma
EP2504000A1 (en) Transcription factor inhibitors and related compositions, formulations and methods
Deng et al. Boronic acid: A novel pharmacophore targeting Src homology 2 (SH2) domain of STAT3
US20240132486A1 (en) Rnf4 targeting compounds and uses thereof
RU2680138C2 (ru) Трициклические ингибиторы гиразы
US20220089531A1 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US8586749B2 (en) Compounds that suppress cancer cells and exhibit antitumor activity
CN103113274B (zh) Ras和HDAC双重抑制剂及其制备方法和用途
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
US20240239787A1 (en) Compounds for use in the treatment of cancer
US20220288033A1 (en) Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction
JP2021526139A (ja) マイトジェン活性化プロテインキナーゼキナーゼ７阻害剤
HK1187921A (en) Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160908

Address after: Ontario, Canada

Applicant after: Univ Toronto

Applicant after: UTI Partners Ltd

Applicant after: UNIV INDIANA RES &AMP

Address before: Ontario, Canada

Applicant before: Univ Toronto

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190409

Termination date: 20200524

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1218709

Country of ref document: HK